IASLC 2019 Mesothelioma Meeting (#MESO19)
GOAL AND PURPOSE:
This IASLC-sponsored meeting will update attendees regarding ongoing clinical trials of the newest mesothelioma therapies. The meeting presenters summarize the data on relevant targets for new therapies. Data on preclinical and early clinical data are presented for each of the drugs directed against these targets. The meeting also presents data on early predictive biomarkers. There are also presentations from fellows and young investigators-in-training, and debates about controversial topics. The meeting is a unique resource for clinical investigators, including those in academia, clinical practice and industry.
Healthcare professionals who diagnose and treat patients with mesothelioma, including:
- Medical oncologists
- Thoracic surgeons
- Radiation oncologists
- Advanced practice nurses and physicians' assistants.
(The meeting is closed except for those invited and IASLC members.)
- Provide a forum for clinical mesothelioma investigators to understand the science behind emerging therapies; and
- Recognize and plan the most novel and relevant scientific trials of new therapies.
Registration opening soon!
Contact email@example.com for more information on sponsorship opportunities.
Michele Carbone, MD PhD, Harvey Pass MD, Rafael Bueno MD, Anne Tsao MD
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.